Novel Bruton’s Tyrosine Kinase inhibitor remibrutinib: Drug‐drug interaction potential as a victim of CYP3A4 inhibitors based on clinical data and PBPK modeling

Remibrutinib, a novel oral Bruton’s Tyrosine Kinase inhibitor (BTKi) is highly selective for BTK, potentially mitigating the side effects of other BTKis. Enzyme phenotyping identified CYP3A4 to be the predominant elimination pathway of remibrutinib. The impact of concomitant treatment with CYP3A4 in...

Descripción completa

Detalles Bibliográficos
Autores principales: Huth, Felix, Schiller, Hilmar, Jin, Yi, Poller, Birk, Schuhler, Carole, Weis, Wendy, Woessner, Ralph, Drollmann, Anton, End, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8742645/
https://www.ncbi.nlm.nih.gov/pubmed/34432364
http://dx.doi.org/10.1111/cts.13126

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8742645/
https://www.ncbi.nlm.nih.gov/pubmed/34432364
http://dx.doi.org/10.1111/cts.13126

Ejemplares similares